SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH
Award amount
$149,919Program and phase
SBIR · Phase IAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Biotex, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- SUH7H6LEZTS2
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel wearable rotating magnetic field therapy device targeting treatment of brain cancers
- Novel 3-D Printed Implant for Improved Hemodialysis Access
- Improving Repair of Female Congenital and Reproductive Anomalies
- Improved Esophageal Safety in Atrial Fibrillation Elimination
- Improved Esophageal Safety in Atrial Fibrillation Elimination
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
60 SBIR/STTR records share this UEI (1997–2025). Reported award amounts total $24,544,336. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Environmental Protection Agency, Department of Defense, National Science Foundation, Department of Agriculture, National Aeronautics and Space Administration